Quoin Pharmaceuticals Company Insiders
| QNRX Stock | USD 0.28 0.02 6.33% |
Slightly above 80 percent of all Quoin Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Quoin Pharmaceuticals Ltd suggests that a fairly large number of insiders are very bullish. Quoin Pharmaceuticals employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 7 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive.
Insider Sentiment 80
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-12-23 | Gordon Dunn | Acquired 122221 @ 0.45 | View | ||
| 2024-09-09 | Gordon Dunn | Acquired 8856 @ 0.79 | View | ||
| 2024-09-04 | Denise P Carter | Acquired 31813 @ 0.78 | View | ||
| 2024-09-03 | Michael Myers | Acquired 800 @ 0.62 | View | ||
| 2024-06-07 | Dennis Langer | Disposed 297 @ 0.73 | View |
Monitoring Quoin Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Quoin |
Quoin Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4272) % which means that it has lost $0.4272 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2056) %, meaning that it created substantial loss on money invested by shareholders. Quoin Pharmaceuticals' management efficiency ratios could be used to measure how well Quoin Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.56 in 2025. Return On Capital Employed is likely to drop to -1.32 in 2025. At this time, Quoin Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 822.5 M in 2025, despite the fact that Other Assets are likely to grow to (61.56).Common Stock Shares Outstanding is likely to drop to about 4.5 M in 2025. Net Loss is likely to drop to about (8.9 M) in 2025
Quoin Pharmaceuticals Workforce Comparison
Quoin Pharmaceuticals Ltd is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 133. Quoin Pharmaceuticals holds roughly 3.0 in number of employees claiming about 2.26% of equities under Health Care industry.
Quoin Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Quoin Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Quoin Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Quoin Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Myers over six months ago Acquisition by Michael Myers of 5322 shares of Quoin Pharmaceuticals at 0.6558 subject to Rule 16b-3 | ||
Michael Myers over six months ago Acquisition by Michael Myers of 800 shares of Quoin Pharmaceuticals at 0.619 subject to Rule 16b-3 | ||
Langer Dennis over six months ago Disposition of 297 shares by Langer Dennis of Quoin Pharmaceuticals at 0.732 subject to Rule 16b-3 | ||
Denise Carter over a year ago Acquisition by Denise Carter of 80966 shares of Quoin Pharmaceuticals subject to Rule 16b-3 | ||
Cooper Joseph Patrick over a year ago Quoin Pharmaceuticals exotic insider transaction detected |
Quoin Pharmaceuticals Notable Stakeholders
A Quoin Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Quoin Pharmaceuticals often face trade-offs trying to please all of them. Quoin Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Quoin Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Myers | CEO CoFounder | Profile | |
| Gordon JD | Chief Officer | Profile | |
| Denise Carter | COO CoFounder | Profile |
About Quoin Pharmaceuticals Management Performance
The success or failure of an entity such as Quoin Pharmaceuticals often depends on how effective the management is. Quoin Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Quoin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Quoin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.56) | |
| Return On Capital Employed | (1.26) | (1.32) | |
| Return On Assets | (0.57) | (0.54) | |
| Return On Equity | (0.97) | (1.02) |
Please note, the imprecision that can be found in Quoin Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Quoin Pharmaceuticals Ltd. Check Quoin Pharmaceuticals' Beneish M Score to see the likelihood of Quoin Pharmaceuticals' management manipulating its earnings.
Quoin Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Quoin Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Quoin Pharmaceuticals within its industry.Quoin Pharmaceuticals Manpower Efficiency
Return on Quoin Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3B | |
| Net Loss Per Executive | 3B | |
| Working Capital Per Employee | 3.6M | |
| Working Capital Per Executive | 3.6M |
Additional Tools for Quoin Stock Analysis
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.